Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)<\/title>\r\n <meta name=\"viewport\" content=\"width=device-width, initial-scale=1\" \/>\r\n <meta name=\"description\" content=\"Primary genes\/pathways in bone-tropic breast cancer with candidate approaches (natural compounds, off-label options, and approved oncology medicines), plus a simple prioritization strategy, practical research-oriented frameworks, and next steps.\" \/>\r\n <meta name=\"robots\" content=\"index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1\" \/>\r\n <meta name=\"author\" content=\"Research Team Art of Healing Cancer\" \/>\r\n <link rel=\"canonical\" href=\"https:\/\/www.example.com\/canonical-placeholder\" \/>\r\n <link rel=\"alternate\" hreflang=\"en\" href=\"https:\/\/www.example.com\/canonical-placeholder\" \/>\r\n\r\n \r\n <meta name=\"keywords\" content=\"bone metastasis, breast cancer, CXCR4 CXCL12, PTK2 FAK, DOCK4, MMPs, PTHrP PTHLH, RANKL OPG, TGF-\u03b2, IL11 IL1B IL6, DKK1 SOST, JAG1 Notch, PI3K AKT mTOR, VEGFA HIF-1\u03b1, HSP90, ESR1 GATA3 NAT1 SCUBE2, antiresorptives, denosumab, zoledronic acid, prioritization strategy, research frameworks\" \/>\r\n\r\n \r\n <meta property=\"og:type\" content=\"article\" \/>\r\n <meta property=\"og:title\" content=\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\" \/>\r\n <meta property=\"og:description\" content=\"Genes\/pathways to know, candidate approaches, a practical prioritization, and research-oriented frameworks for bone-tropic disease.\" \/>\r\n <meta property=\"og:url\" content=\"https:\/\/www.example.com\/canonical-placeholder\" \/>\r\n <meta property=\"og:site_name\" content=\"Art of Healing Cancer\" \/>\r\n <meta property=\"og:locale\" content=\"en_US\" \/>\r\n <meta property=\"og:image\" content=\"https:\/\/www.example.com\/path\/to\/og-image-part8.jpg\" \/>\r\n <meta property=\"og:image:alt\" content=\"Grid of pathways and candidate approaches for bone-tropic metastasis\" \/>\r\n <meta property=\"article:section\" content=\"Oncology\" \/>\r\n <meta property=\"article:published_time\" content=\"2025-08-19T00:00:00+05:30\" \/>\r\n <meta property=\"article:modified_time\" content=\"2025-08-19T00:00:00+05:30\" \/>\r\n\r\n \r\n <meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n <meta name=\"twitter:title\" content=\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\" \/>\r\n <meta name=\"twitter:description\" content=\"Primary genes\/pathways with candidate approaches, prioritization strategy, and practical frameworks.\" \/>\r\n <meta name=\"twitter:image\" content=\"https:\/\/www.example.com\/path\/to\/og-image-part8.jpg\" \/>\r\n <meta name=\"twitter:image:alt\" content=\"Pathway map and treatment layers\" \/>\r\n <meta name=\"twitter:site\" content=\"@ArtOfHealingCancer\" \/>\r\n\r\n \r\n <meta property=\"article:tag\" content=\"Bone Metastasis\" \/>\r\n <meta property=\"article:tag\" content=\"Breast Cancer\" \/>\r\n <meta property=\"article:tag\" content=\"CXCR4\/CXCL12\" \/>\r\n <meta property=\"article:tag\" content=\"RANKL\/OPG\" \/>\r\n <meta property=\"article:tag\" content=\"TGF-\u03b2\" \/>\r\n <meta property=\"article:tag\" content=\"PI3K\u2013AKT\u2013mTOR\" \/>\r\n <meta property=\"article:tag\" content=\"Antiresorptives\" \/>\r\n <meta property=\"article:tag\" content=\"Prioritization Strategy\" \/>\r\n <meta property=\"article:tag\" content=\"Research Frameworks\" \/>\r\n\r\n \r\n <script type=\"application\/ld+json\">\r\n {\r\n \"@context\":\"https:\/\/schema.org\",\r\n \"@type\":\"Article\",\r\n \"headline\":\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\",\r\n \"description\":\"Primary genes\/pathways in bone-tropic breast cancer with candidate approaches (natural compounds, off-label options, and approved oncology medicines), plus a simple prioritization strategy, practical research-oriented frameworks, and next steps.\",\r\n \"inLanguage\":\"en\",\r\n \"datePublished\":\"2025-08-19\",\r\n \"dateModified\":\"2025-08-19\",\r\n \"author\":{\"@type\":\"Organization\",\"name\":\"Research Team Art of Healing Cancer\"},\r\n \"publisher\":{\"@type\":\"Organization\",\"name\":\"Art of Healing Cancer\"},\r\n \"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.example.com\/canonical-placeholder\"},\r\n \"keywords\":[\"Bone Metastasis\",\"Breast Cancer\",\"CXCR4\/CXCL12\",\"RANKL\/OPG\",\"TGF-\u03b2\",\"PI3K\u2013AKT\u2013mTOR\",\"Antiresorptives\",\"Prioritization Strategy\",\"Research Frameworks\",\"MMPs\",\"FAK\",\"Notch\",\"Wnt\",\"VEGFA\/HIF-1\u03b1\",\"HSP90\",\"Dormancy\"],\r\n \"image\":\"https:\/\/www.example.com\/path\/to\/og-image-part8.jpg\",\r\n \"articleSection\":\"Oncology\"\r\n }\r\n <\/script>\r\n\r\n \r\n <script type=\"application\/ld+json\">\r\n {\r\n \"@context\":\"https:\/\/schema.org\",\r\n \"@type\":\"BreadcrumbList\",\r\n \"itemListElement\":[\r\n {\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.example.com\/\"},\r\n {\"@type\":\"ListItem\",\"position\":2,\"name\":\"Art of Healing Cancer\",\"item\":\"https:\/\/www.example.com\/series\/art-of-healing-cancer\"},\r\n {\"@type\":\"ListItem\",\"position\":3,\"name\":\"Part 8 \u2014 Pathway Targets & Candidate Approaches\"}\r\n ]\r\n }\r\n <\/script>\r\n\r\n <style>\r\n \/* ===== Brand tokens (WCAG AA) \u2014 suffix 6112 ===== *\/\r\n :root{\r\n --navy-6112:#0D2B5A; --navy-dark-6112:#0B2240;\r\n --aqua-6112:#00B7C7; --aqua2-6112:#20C2CF;\r\n --white-6112:#FFFFFF; --gray-6112:#E9EEF4;\r\n --graphite-6112:#1F2A37; --muted-6112:#4B5563;\r\n --border-6112:#d7e0ea; --soft-6112:#F7FBFD;\r\n --warn-6112:#B45309; --warnbg-6112:#FFF7ED;\r\n }\r\n html,body{margin:0;padding:0}\r\n body.page-6112{\r\n color:var(--graphite-6112); background:#ffffff;\r\n font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,\"Apple Color Emoji\",\"Segoe UI Emoji\";\r\n font-size:17px; line-height:1.65; -webkit-font-smoothing:antialiased; text-rendering:optimizeLegibility;\r\n }\r\n .wrap-6112{max-width:1080px;margin:0 auto;padding:0 22px}\r\n\r\n \/* ===== Hero ===== *\/\r\n .hero-6112{\r\n background:\r\n radial-gradient(1200px 420px at 18% 0%, rgba(32,194,207,.12), transparent 60%),\r\n linear-gradient(180deg,var(--navy-6112),var(--navy-dark-6112));\r\n color:var(--white-6112);\r\n padding:48px 0 28px;\r\n border-bottom:1px solid rgba(255,255,255,.12);\r\n box-shadow:0 12px 24px rgba(13,43,90,.18);\r\n }\r\n .h1-6112{margin:0 0 10px;font-size:clamp(28px,4.4vw,44px);line-height:1.18;font-weight:850;letter-spacing:.2px}\r\n .underline-6112{height:6px;width:150px;border-radius:999px;background:linear-gradient(90deg,var(--aqua-6112),var(--aqua2-6112));margin-top:10px}\r\n .meta-6112{margin-top:14px;display:flex;flex-wrap:wrap;gap:10px 18px}\r\n .meta-6112 .item-6112{color:#dff7fb;font-weight:700;font-size:14px}\r\n .sub-6112{margin-top:12px;font-size:15px;color:#eef6fb}\r\n\r\n \/* ===== Article card ===== *\/\r\n .card-6112{background:#fff;border:1px solid var(--border-6112);border-radius:18px;box-shadow:0 1px 2px rgba(13,43,90,.06),0 10px 24px rgba(13,43,90,.08);overflow:hidden;margin:28px 0 72px}\r\n .head-6112{padding:16px 20px;background:linear-gradient(180deg,#f4f8fb 0%,#eef5fa 100%);border-bottom:1px solid var(--border-6112)}\r\n .note-6112{border-left:5px solid var(--aqua-6112);background:var(--soft-6112);padding:12px 14px;border-radius:10px;color:var(--muted-6112);font-size:14px}\r\n\r\n \/* ===== Caution box ===== *\/\r\n .caution-6112{display:flex;gap:10px;align-items:flex-start;margin-top:12px;padding:12px 14px;border:1px solid #F5D0A9;background:var(--warnbg-6112);border-radius:12px;color:var(--warn-6112);font-weight:700}\r\n\r\n \/* ===== Bands & pills ===== *\/\r\n .band-6112{\r\n margin:28px 0 12px; padding:0; position:relative;\r\n color:var(--navy-dark-6112); font-size:20px; font-weight:800;\r\n }\r\n .band-6112 span{\r\n display:inline-block; padding:10px 14px; border-radius:12px;\r\n background:linear-gradient(90deg, #f2f7fb, #eaf2f9);\r\n border:1px solid var(--border-6112);\r\n }\r\n .band-6112::before{\r\n content:\"\"; position:absolute; left:-6px; top:50%; transform:translateY(-50%);\r\n width:6px; height:28px; border-radius:4px;\r\n background:linear-gradient(180deg,var(--aqua-6112),var(--aqua2-6112));\r\n }\r\n .pill-6112{display:inline-block;margin:16px 0 8px;padding:6px 12px;background:var(--soft-6112);border:1px solid var(--border-6112);border-radius:999px;font-size:15px;font-weight:800;color:var(--navy-6112)}\r\n .p-6112{margin:0 0 14px}\r\n .ul-6112{margin:0 0 14px 22px}\r\n .ul-6112 li{margin:6px 0}\r\n\r\n \/* ===== TOC ===== *\/\r\n .toc-6112{margin:12px 0 18px;padding:12px 14px;border:1px dashed var(--border-6112);border-radius:12px;background:#FAFDFF}\r\n .toc-6112 a{color:var(--navy-6112);text-decoration:none;font-weight:800}\r\n .toc-6112 a:hover{text-decoration:underline}\r\n\r\n \/* ===== Grid & gene cards ===== *\/\r\n .grid-6112{display:grid;gap:14px;grid-template-columns:1fr}\r\n @media (min-width:760px){.grid-6112{grid-template-columns:1fr 1fr}}\r\n .gene-6112{border:1px solid var(--border-6112);border-radius:14px;background:linear-gradient(180deg,#ffffff 0%,#f8fcfd 100%);box-shadow:0 6px 14px rgba(13,43,90,.06);overflow:hidden}\r\n .geneHead-6112{background:linear-gradient(90deg,var(--aqua-6112),var(--aqua2-6112));color:#fff;padding:10px 14px;display:flex;justify-content:space-between;align-items:center}\r\n .geneTitle-6112{font-weight:900;letter-spacing:.2px}\r\n .geneTag-6112{font-size:12px;font-weight:800;opacity:.95}\r\n .geneBody-6112{padding:12px 14px}\r\n\r\n \/* ===== Summary table ===== *\/\r\n .tableWrap-6112{margin:8px 0 18px; overflow-x:auto}\r\n table.table-6112{width:100%; border-collapse:separate; border-spacing:0; min-width:900px; border:1px solid var(--border-6112); border-radius:12px; overflow:hidden}\r\n .table-6112 caption{text-align:left; padding:10px 12px; font-weight:800; color:var(--navy-dark-6112)}\r\n .table-6112 thead th{background:linear-gradient(90deg,var(--navy-6112),var(--navy-dark-6112));color:#fff;padding:12px 14px;font-size:14px;text-align:left}\r\n .table-6112 tbody td{padding:12px 14px;vertical-align:top;border-top:1px solid var(--border-6112);background:#fff}\r\n .table-6112 tbody tr:nth-child(even) td{background:#f7fbfd}\r\n .kicker-6112{display:inline-block;padding:2px 8px;border-radius:999px;background:var(--aqua-6112);color:#fff;font-size:12px;font-weight:800}\r\n\r\n \/* ===== Details\/summary accordion ===== *\/\r\n details.accord-6112{border-top:1px dashed var(--border-6112);padding-top:10px;margin-top:10px}\r\n details.accord-6112 > summary{cursor:pointer;font-weight:900;color:var(--navy-6112)}\r\n details.accord-6112[open] > summary{opacity:.9}\r\n\r\n \/* ===== Chips ===== *\/\r\n .chips-6112{display:grid;gap:10px;margin-top:12px;grid-template-columns:repeat(auto-fill,minmax(180px,1fr))}\r\n .chip-6112{background:var(--soft-6112);border:1px solid var(--border-6112);padding:10px 12px;border-radius:12px;font-weight:700;color:var(--navy-6112)}\r\n\r\n \/* ===== Footer ===== *\/\r\n .foot-6112{margin-top:22px;font-size:13px;color:var(--muted-6112);border-top:1px dashed var(--border-6112);padding-top:14px}\r\n <\/style>\r\n<\/head>\r\n<body class=\"page-6112\">\r\n <header class=\"hero-6112\" role=\"banner\">\r\n <div class=\"wrap-6112\">\r\n <h1 class=\"h1-6112\">Part 8 \u2014 Pathway Targets & Candidate Approaches<\/h1>\r\n <div class=\"underline-6112\" aria-hidden=\"true\"><\/div>\r\n <div class=\"meta-6112\" aria-label=\"Article metadata\">\r\n <div class=\"item-6112\">Author: <strong>Research Team Art of Healing Cancer<\/strong><\/div>\r\n <div class=\"item-6112\">Credentials: <strong>Oncology research & editorial team<\/strong><\/div>\r\n <div class=\"item-6112\">Updated: <strong>August 19, 2025<\/strong><\/div>\r\n <div class=\"item-6112\">Estimated reading time: <strong>\u224812\u201316 min<\/strong><\/div>\r\n <\/div>\r\n <p class=\"sub-6112\">Primary genes\/pathways with candidate approaches (natural, off-label, approved), a simple prioritization, research-oriented frameworks, and actionable next steps.<\/p>\r\n <\/div>\r\n <\/header>\r\n\r\n <main>\r\n <div class=\"wrap-6112\">\r\n <article class=\"card-6112\" itemscope itemtype=\"https:\/\/schema.org\/Article\">\r\n <div class=\"head-6112\">\r\n <div class=\"note-6112\"><strong>Note:<\/strong> The body text below is your content, structured for readability. Roman numerals are rendered as major section headings. This is educational content and not medical advice.<\/div>\r\n <div class=\"caution-6112\" role=\"note\" aria-label=\"Important notes\">\r\n <div>\u26a0\ufe0f<\/div>\r\n <div>\r\n <strong>Important notes:<\/strong>\r\n <ul class=\"ul-6112\" style=\"margin-top:6px\">\r\n <li>Natural molecules: mostly preclinical evidence; human efficacy\/dosing\/safety for cancer are not established; interactions with therapies are possible.<\/li>\r\n <li>Off-label medicines: require clinician oversight within an evidence-based plan or trials.<\/li>\r\n <li>Approved oncology drugs: listed where they target the biology, even if approvals are for other cancers or endpoints.<\/li>\r\n <li>This section is informational and not medical advice.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n\r\n <div class=\"content-6112\" itemprop=\"articleBody\">\r\n \r\n <nav class=\"toc-6112\" aria-label=\"On-page navigation\">\r\n <strong>Quick nav:<\/strong>\r\n <div class=\"chips-6112\">\r\n <a class=\"chip-6112\" href=\"#primary-genes\">Primary Genes\/Pathways & Candidate Approaches<\/a>\r\n <a class=\"chip-6112\" href=\"#vi-prioritization\">VI) Prioritization Strategy<\/a>\r\n <a class=\"chip-6112\" href=\"#vii-frameworks\">VII) Practical Frameworks<\/a>\r\n <a class=\"chip-6112\" href=\"#viii-spine-recap\">VIII) Spine Recap<\/a>\r\n <a class=\"chip-6112\" href=\"#ix-next-steps\">IX) What To Do Next<\/a>\r\n <\/div>\r\n <\/nav>\r\n\r\n \r\n <h2 id=\"primary-genes\" class=\"band-6112\"><span>Primary Genes\/Pathways With Candidate Approaches (Natural, Off-Label, and Approved Cancer Medications)<\/span><\/h2>\r\n\r\n \r\n <div class=\"tableWrap-6112\" role=\"region\" aria-label=\"Pathway summary table\">\r\n <table class=\"table-6112\">\r\n <caption>Quick reference: pathway \u2192 natural \u2192 off-label \u2192 approved (notes)<\/caption>\r\n <thead>\r\n <tr>\r\n <th scope=\"col\">Pathway \/ Gene<\/th>\r\n <th scope=\"col\">Natural (preclinical)<\/th>\r\n <th scope=\"col\">Off-label (conceptual)<\/th>\r\n <th scope=\"col\">Approved (notes)<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td><span class=\"kicker-6112\">CXCR4 (CXCL12\/SDF-1)<\/span><\/td>\r\n <td>Resveratrol; EGCG<\/td>\r\n <td>Plerixafor (CXCR4 antagonist)<\/td>\r\n <td>No broad solid tumor approval for metastasis prevention; inhibitors investigational; hematologic uses in trials.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">PTK2 \/ FAK<\/span><\/td>\r\n <td>Curcumin<\/td>\r\n <td>Defactinib (investigational)<\/td>\r\n <td>No broad oncology approval; trial-based.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">DOCK4 (Rac motility)<\/span><\/td>\r\n <td>Berberine<\/td>\r\n <td>Fasudil (ROCK inhibitor)<\/td>\r\n <td>No specific approvals for this axis in breast metastasis.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">MMPs (1\/2\/9\/13)<\/span><\/td>\r\n <td>EGCG; Curcumin<\/td>\r\n <td>Doxycycline (MMP modulation)<\/td>\r\n <td>No MMPi approvals for anti-metastatic therapy.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">PTHLH (PTHrP)<\/span><\/td>\r\n <td>Genistein<\/td>\r\n <td>Cinacalcet (contextual)<\/td>\r\n <td>No direct PTHrP drug; downstream control via antiresorptives.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">RANKL \/ OPG axis<\/span><\/td>\r\n <td>Curcumin; Vitamin D \/ Omega-3<\/td>\r\n <td>Oral bisphosphonates (e.g., clodronate)<\/td>\r\n <td>Denosumab; Zoledronic acid; Pamidronate \u2014 reduce SREs in metastatic bone disease.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">TGF-\u03b2 pathway<\/span><\/td>\r\n <td>Sulforaphane; EGCG<\/td>\r\n <td>Losartan (modulating)<\/td>\r\n <td>Multiple agents investigational; no broad approval for prevention.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">IL11 \/ IL1B \/ IL6<\/span><\/td>\r\n <td>Boswellia (AKBA); Curcumin<\/td>\r\n <td>Anakinra; Tocilizumab<\/td>\r\n <td>Approved in inflammatory diseases; oncology use trial-based.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">DKK1 & SOST (Wnt antagonists)<\/span><\/td>\r\n <td>Resveratrol; Quercetin<\/td>\r\n <td>Romosozumab (osteoporosis; CV cautions)<\/td>\r\n <td>Anti-DKK1 agents investigational; no Wnt restoration approval for solid tumors.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">JAG1 \/ Notch<\/span><\/td>\r\n <td>EGCG<\/td>\r\n <td>Gamma-secretase inhibitors (e.g., nirogacestat)<\/td>\r\n <td>Nirogacestat approved for desmoid tumors; breast bone metastasis use investigational.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">PI3K \/ AKT \/ mTOR<\/span><\/td>\r\n <td>Berberine; Resveratrol<\/td>\r\n <td>\u2014<\/td>\r\n <td>Alpelisib; Everolimus; Capivasertib (jurisdiction-dependent).<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">VEGFA \/ HIF-1\u03b1<\/span><\/td>\r\n <td>Curcumin; Resveratrol; Honokiol<\/td>\r\n <td>Bevacizumab (context-dependent)<\/td>\r\n <td>Anti-VEGF\/VEGFR agents approved in various cancers; not for preventing bone metastasis in breast cancer.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">HSP90AA1<\/span><\/td>\r\n <td>Withanolides (Withania somnifera)<\/td>\r\n <td>\u2014<\/td>\r\n <td>No broad approvals for HSP90 inhibitors in solid tumors.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">ESR1 \/ GATA3 \/ NAT1 \/ SCUBE2<\/span><\/td>\r\n <td>Genistein (context-dependent); Curcumin (immune-niche)<\/td>\r\n <td>Metronomic cyclophosphamide (Treg modulation; exploratory)<\/td>\r\n <td>Endocrine therapy; CDK4\/6 inhibitors; SERD\/SERM combinations (biomarker-guided).<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n\r\n \r\n <div class=\"grid-6112\">\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">CXCR4 (homing\/retention; CXCL12\/SDF-1 axis)<\/div>\r\n <div class=\"geneTag-6112\">Homing<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Resveratrol<\/strong> or <strong>EGCG<\/strong>: Reported to down-modulate CXCR4 signaling and migration in preclinical cancer systems.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Plerixafor<\/strong>: CXCR4 antagonist approved for hematopoietic stem-cell mobilization; conceptually disrupts marrow homing\/retention.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication (any cancer)<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li>None broadly approved for solid tumors to block CXCR4 in metastasis; several CXCR4 inhibitors are investigational in oncology. Some leukemias\/lymphomas use CXCR4-directed strategies in trials.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">PTK2\/FAK (integrin signaling; adhesion\/migration)<\/div>\r\n <div class=\"geneTag-6112\">Adhesion\/Migration<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Curcumin<\/strong>: Inhibits FAK signaling and reduces migration\/invasion in preclinical models.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Defactinib<\/strong>: Oral FAK inhibitor under investigation in solid tumors; not standard of care.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>No FAK inhibitor has a broad oncology approval at present; use is trial-based.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">DOCK4 (Rac-mediated motility)<\/div>\r\n <div class=\"geneTag-6112\">Motility<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Berberine<\/strong>: Broad anti-motility\/invasion effects in preclinical models; may indirectly modulate Rac signaling.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Fasudil<\/strong>: A ROCK inhibitor with cytoskeletal modulation; oncology use is experimental.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>None specific to DOCK\/Rac pathway for breast cancer metastasis; ROCK inhibitors remain investigational in oncology.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">MMPs (MMP1\/2\/9\/13; extracellular matrix remodeling)<\/div>\r\n <div class=\"geneTag-6112\">Invasion<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>EGCG<\/strong> or <strong>curcumin<\/strong>: Preclinical suppression of MMP expression\/activity.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Doxycycline<\/strong>: Sub-antimicrobial dosing can inhibit MMPs; used historically as a broad MMP modulator.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>No MMP inhibitor is approved for anti-metastatic therapy due to past toxicity\/efficacy issues of first-generation agents.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">PTHLH (PTHrP; initiates osteolytic switch)<\/div>\r\n <div class=\"geneTag-6112\">Osteolysis<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Genistein<\/strong>: Preclinical modulation of osteoclastogenesis and the RANKL\/OPG balance.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Cinacalcet<\/strong>: Calcimimetic used for hyperparathyroidism and PTH\/PTHrP-related hypercalcemia; not established as anti-metastatic.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>No direct PTHrP-targeting drug for cancer; downstream axis control via antiresorptives (see RANKL\/OPG) is standard to prevent skeletal-related events.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">RANKL\/OPG axis (osteoclastogenesis driver)<\/div>\r\n <div class=\"geneTag-6112\">Antiresorptive<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Curcumin<\/strong> or <strong>vitamin D\/omega-3 PUFAs<\/strong>: Preclinical influence on RANKL\/OPG and osteoclastogenesis.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Oral bisphosphonates<\/strong> (e.g., clodronate in certain settings) have been used variably outside strict labels; the class impairs osteoclasts.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Denosumab<\/strong>: Monoclonal antibody to RANKL; approved to prevent skeletal-related events in patients with bone metastases from solid tumors.<\/li>\r\n <li><strong>Zoledronic acid, pamidronate<\/strong>: Intravenous bisphosphonates approved to reduce skeletal-related events in metastatic bone disease.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">TGF-\u03b2 pathway (central amplifier of bone metastasis program)<\/div>\r\n <div class=\"geneTag-6112\">Amplifier<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Sulforaphane<\/strong> or <strong>EGCG<\/strong>: Preclinical attenuation of TGF-\u03b2\/SMAD signaling and TGF-\u03b2-induced EMT.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Losartan<\/strong>: Antifibrotic\/TGF-\u03b2-modulating effects studied in oncology contexts; not standard for metastasis control.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>No TGF-\u03b2 pathway inhibitor has a broad metastasis-prevention approval; multiple agents are investigational in solid tumors.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">IL11, IL1B, IL6 (inflammatory, osteoclastogenic cytokines)<\/div>\r\n <div class=\"geneTag-6112\">Cytokines<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Boswellia serrata (AKBA)<\/strong> or <strong>curcumin<\/strong>: Preclinical suppression of NF-\u03baB\/IL-1\u03b2\/IL-6.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Anakinra<\/strong> (IL-1 receptor antagonist) or <strong>tocilizumab<\/strong> (IL-6R inhibitor): Explored in cancer-related inflammation; investigational in bone-tropic disease.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>IL-6 or IL-1 pathway inhibitors are approved for inflammatory diseases, not for cancer metastasis; in oncology, they\u2019re trial-based for select indications.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">DKK1 and SOST (Wnt antagonists; osteoblast suppression)<\/div>\r\n <div class=\"geneTag-6112\">Wnt<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Resveratrol<\/strong> or <strong>quercetin<\/strong>: Preclinical Wnt modulation that can favor osteoblastogenesis.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Romosozumab<\/strong> (anti-sclerostin) has approvals for osteoporosis, not cancer; application in metastasis is experimental and carries cardiovascular risk considerations.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>Anti-DKK1 agents (e.g., in myeloma) are investigational; no Wnt-restorative drug is approved for solid tumor bone metastasis.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">JAG1\/Notch signaling (microenvironment remodeling)<\/div>\r\n <div class=\"geneTag-6112\">Notch<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>EGCG<\/strong>: Reported preclinical effects on Notch signaling.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Gamma-secretase inhibitors<\/strong> (e.g., nirogacestat): Target Notch activation; toxicity requires careful management; use is trial-based.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Nirogacestat<\/strong> is approved for desmoid tumors (Notch-related biology) in some regions; Notch targeting in breast cancer bone metastasis remains investigational.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">PI3K\/AKT\/mTOR (survival\/growth\/metabolic fitness)<\/div>\r\n <div class=\"geneTag-6112\">Survival<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Berberine<\/strong> or <strong>resveratrol<\/strong>: Preclinical inhibition of PI3K\/AKT\/mTOR; effects on proliferation and EMT.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li>None routinely off-label given existing on-label options in breast cancer.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Alpelisib<\/strong> (PI3K\u03b1 inhibitor) for PIK3CA-mutant HR+ metastatic breast cancer.<\/li>\r\n <li><strong>Everolimus<\/strong> (mTOR inhibitor) for HR+ metastatic breast cancer in combination with endocrine therapy.<\/li>\r\n <li><strong>Capivasertib<\/strong> (AKT inhibitor) has approvals in HR+ breast cancer with pathway alterations in some jurisdictions; availability varies.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">VEGFA\/HIF-1\u03b1 (angiogenesis\/hypoxia response)<\/div>\r\n <div class=\"geneTag-6112\">Angiogenesis<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Curcumin<\/strong>, <strong>resveratrol<\/strong>, or <strong>honokiol<\/strong>: Preclinical anti-angiogenic and HIF-1\u03b1-lowering effects.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Bevacizumab<\/strong> (anti-VEGF): Mixed data in breast cancer; not standard for bone-specific control; consider only in trial settings or specific regulatory contexts.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Bevacizumab<\/strong> and other anti-VEGF\/VEGFR agents (e.g., ramucirumab, aflibercept, sorafenib, sunitinib, pazopanib) are approved in various cancers for anti-angiogenesis, not specifically for bone metastasis prevention in breast cancer.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">HSP90AA1 (chaperone dependency)<\/div>\r\n <div class=\"geneTag-6112\">Stress Support<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Withanolides<\/strong> (Withania somnifera): Preclinical HSP90 modulation.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li>None standard; HSP90 inhibitors remain investigational.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>No HSP90 inhibitor has broad approval in solid tumors.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">ESR1\/GATA3\/NAT1\/SCUBE2 (luminal\/dormancy\/immune niche)<\/div>\r\n <div class=\"geneTag-6112\">Dormancy<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Genistein<\/strong> (phytoestrogen): Interacts with ER signaling; context-dependent effects; <strong>curcumin<\/strong> for immune-niche modulation preclinically.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Metronomic cyclophosphamide<\/strong> for Treg modulation is exploratory; use is individualized.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Endocrine therapies<\/strong> (tamoxifen, aromatase inhibitors, fulvestrant) are standards in HR+ breast cancer.<\/li>\r\n <li><strong>CDK4\/6 inhibitors<\/strong> (palbociclib, ribociclib, abemaciclib) are approved in HR+ metastatic breast cancer and can delay progression, including in bone-dominant disease.<\/li>\r\n <li><strong>SERDs\/SERMs<\/strong> and targeted combinations are approved in specific contexts; selection is biomarker-guided.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n <\/div>\r\n\r\n \r\n <h2 id=\"vi-prioritization\" class=\"band-6112\"><span>VI) Prioritization Strategy \u2014 In Simple Terms<\/span><\/h2>\r\n <p class=\"p-6112\">Not every target in the bone metastasis pathway is equally powerful. Some are \u201cmaster switches\u201d that, if flipped off, weaken many downstream processes at once. Others are important but more situational\u2014best addressed if tests show they are dominant in a particular person\u2019s cancer. Prioritization helps decide what to target first.<\/p>\r\n\r\n <div class=\"pill-6112\">Tier 1: Master feedbacks (RANKL\/osteoclasts + TGF-\u03b2)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why top priority:<\/strong> RANKL turns on osteoclasts (the bone-degrading cells). When osteoclasts break down bone, growth factors (especially TGF-\u03b2) pour out of the bone matrix. TGF-\u03b2 then pushes tumor cells to make more osteolysis-promoting signals (like IL-11), \u201cmolecular scissors\u201d (MMPs), and homing\/retention tools (CXCR4), which worsens bone destruction and tumor growth. Together, these two form the core of the vicious cycle.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> Use approved anti-resorptive therapy to reduce bone breakdown (and therefore TGF-\u03b2 release). Consider clinical trials or research strategies aimed at dampening TGF-\u03b2 signaling.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"pill-6112\">Tier 2: Seeding\/retention (CXCR4 axis)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why next:<\/strong> CXCR4 acts like a GPS that guides cancer cells to bone marrow (rich in CXCL12) and helps them stick around.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> Consider clinical trial options that interfere with the CXCR4\u2013CXCL12 connection, especially when molecular testing suggests a bone-tropic profile.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"pill-6112\">Tier 3: Fitness\/expansion (PI3K\/AKT\/mTOR and angiogenesis)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why important:<\/strong> Bone marrow is a tough environment\u2014low oxygen, fluctuating nutrients, immune pressure. PI3K\/AKT\/mTOR helps cancer cells adapt and keep growing. Angiogenesis programs (HIF-1\u03b1\/VEGF) build new blood vessels to feed growth.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> Where approved and biomarker-appropriate, use PI3K\/mTOR\/AKT inhibitors. Consider anti-angiogenic approaches in indicated settings or within trials.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"pill-6112\">Tier 4: Adhesion\/MMP\/Notch\/Wnt (context-driven add-ons)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why conditional:<\/strong> These targets matter, but their dominance varies by tumor.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> When tests show reliance on integrin\/FAK, MMPs, Notch (JAG1), or Wnt antagonism (DKK1\/SOST), consider research-focused strategies alongside Tier 1\u20133 priorities.<\/li>\r\n <\/ul>\r\n\r\n <p class=\"p-6112\"><strong>In short:<\/strong> Start by weakening the core loop (RANKL and TGF-\u03b2), then block homing\/retention (CXCR4), then reduce the tumor\u2019s ability to thrive in bone (PI3K\/mTOR\/AKT and angiogenesis). Add adhesion\/MMP\/Notch\/Wnt tactics based on tumor-specific evidence.<\/p>\r\n\r\n \r\n <h2 id=\"vii-frameworks\" class=\"band-6112\"><span>VII) Practical Frameworks to Explore (Research-Oriented) \u2014 In Simple Terms<\/span><\/h2>\r\n <p class=\"p-6112\">These are examples of how to put the prioritization into action. They are not medical advice but illustrate how clinicians and researchers might tailor strategies to tumor biology.<\/p>\r\n\r\n <div class=\"grid-6112\">\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">ER+ bone-dominant disease with PI3K activation<\/div>\r\n <div class=\"geneTag-6112\">HR+ \/ PI3K<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Build the backbone<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Endocrine therapy (because the tumor is hormone receptor positive).<\/li>\r\n <li>Add a PI3K or mTOR inhibitor if the pathway is activated (based on biomarkers and approvals).<\/li>\r\n <li>Include an anti-resorptive (e.g., denosumab or zoledronic acid) to reduce bone breakdown and TGF-\u03b2 release.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Consider research add-ons<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Clinical trials targeting TGF-\u03b2 (to mute the amplifier) or CXCR4 (to disrupt homing\/retention) when biology suggests these are active.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">Inflammatory signature (high IL-1\u03b2\/IL-6) with osteolytic features<\/div>\r\n <div class=\"geneTag-6112\">Cytokine-high<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Stabilize the bone<\/div>\r\n <ul class=\"ul-6112\"><li>Start anti-resorptive therapy to slow osteoclasts and reduce TGF-\u03b2 release.<\/li><\/ul>\r\n <div class=\"pill-6112\">Treat the whole patient<\/div>\r\n <ul class=\"ul-6112\"><li>Use standard systemic therapy appropriate to subtype (e.g., endocrine therapy for ER+, chemotherapy for other subtypes).<\/li><\/ul>\r\n <div class=\"pill-6112\">Consider research add-ons<\/div>\r\n <ul class=\"ul-6112\"><li>Trials of cytokine blockade (e.g., IL-1 or IL-6 pathway inhibitors) and\/or TGF-\u03b2 modulation.<\/li><\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">High motility\/adhesion signature (FAK\/MMP)<\/div>\r\n <div class=\"geneTag-6112\">Invasion-high<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Target movement and invasion (research-focused)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Consider trials of FAK inhibitors to impair adhesion\/migration signaling.<\/li>\r\n <li>Dampen local invasion with MMP modulation strategies (e.g., doxycycline) as a research approach.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Combine with core control<\/div>\r\n <ul class=\"ul-6112\"><li>Maintain anti-resorptives and subtype-appropriate systemic therapy to tackle the main loop and disease biology.<\/li><\/ul>\r\n <\/div>\r\n <\/section>\r\n <\/div>\r\n\r\n \r\n <h2 id=\"viii-spine-recap\" class=\"band-6112\"><span>VIII) Why the Spine Often Leads \u2014 But Exceptions Matter (Recap in Simple Terms)<\/span><\/h2>\r\n <ul class=\"ul-6112\">\r\n <li>The spine has a convenient venous \u201chighway\u201d connected to the chest (Batson\u2019s plexus), rich red marrow that attracts tumor cells via CXCL12, and high bone turnover\u2014making it a frequent first site for seeding and growth.<\/li>\r\n <li>But it isn\u2019t always first: pelvis, ribs, and proximal femur are also common early sites. Blood flow, bone stress\/remodeling, tumor surface proteins (chemokine receptors, integrins), and chance can shift the first landing spot.<\/li>\r\n <li><strong>Clinical implication:<\/strong> Do not assume a spinal-first pattern; evaluate the entire skeleton when bone involvement is suspected.<\/li>\r\n <\/ul>\r\n\r\n \r\n <h2 id=\"ix-next-steps\" class=\"band-6112\"><span>IX) What To Do Next: Actionable Steps \u2014 In Simple Terms<\/span><\/h2>\r\n <div class=\"grid-6112\">\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">For patients and caregivers<\/div>\r\n <div class=\"geneTag-6112\">Patient<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Ask about the tumor\u2019s \u201cbone risk\u201d biology<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Features linked to bone spread (ER+\/luminal, high CXCR4, PI3K activation, inflammatory cytokines)? Are biomarker panels available?<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Protect bone health early<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Discuss anti-resorptive therapy; complete dental evaluation first. Ask about calcium\/vitamin D, weight-bearing exercise, and fall-risk reduction.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Speak up about new symptoms<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>New\/worsening back pain, focal bone tenderness, numbness\/weakness \u2192 prompt imaging beyond the spine when warranted.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">For clinicians<\/div>\r\n <div class=\"geneTag-6112\">Clinician<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Stratify risk with what\u2019s available<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Combine clinical factors with molecular markers (luminal signatures, CXCR4, RANKL\/OPG, IL-1\/IL-6, PI3K pathway changes) to tailor surveillance\/supportive care.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Match therapy to biology<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Use guideline-supported systemic therapy for subtype; add anti-resorptives for skeletal event prevention in metastatic bone disease.<\/li>\r\n <li>Explore trial eligibility for TGF-\u03b2, CXCR4, cytokine, FAK, or HSP90-directed strategies where biology points that way.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Choose imaging wisely<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>MRI is excellent for marrow disease; functional PET modalities can detect non-spinal lesions depending on phenotype and availability.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">For researchers<\/div>\r\n <div class=\"geneTag-6112\">Research<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Validate and integrate biomarkers<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Prospective panels\/blood markers for bone tropism: CXCR4\/CXCL12, RANKL\/OPG, IL-11\/IL-1\/IL-6, TGF-\u03b2 responsiveness.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Design enriched trials<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Pair anti-resorptives with targeted inhibitors (TGF-\u03b2, CXCR4, PI3K\/mTOR\/AKT, FAK) in biomarker-selected cohorts; include marrow disease\/SRE\/QoL endpoints.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Focus on dormancy\/reactivation in ER+ disease<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Identify triggers that wake dormant cells; test ways to maintain dormancy or eliminate dormant cells without provoking growth.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n <\/div>\r\n\r\n \r\n <h2 class=\"band-6112\"><span>Tags<\/span><\/h2>\r\n <div class=\"chips-6112\" role=\"list\">\r\n <div class=\"chip-6112\" role=\"listitem\">Bone Metastasis<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Breast Cancer<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Antiresorptives<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">RANKL \/ OPG<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">TGF-\u03b2<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">CXCR4 \/ CXCL12<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">PI3K\u2013AKT\u2013mTOR<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">FAK<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">MMPs<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Notch \/ JAG1<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Wnt \/ DKK1 \/ SOST<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Angiogenesis<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Dormancy<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Research Frameworks<\/div>\r\n <\/div>\r\n\r\n <div class=\"foot-6112\">\u00a9 2025 Art of Healing Cancer \u00b7 Educational content only; not medical advice.<\/div>\r\n <\/div>\r\n <\/article>\r\n <\/div>\r\n <\/main>\r\n<\/body>\r\n<\/html>\r\n","protected":false},"excerpt":{"rendered":"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved) Part 8 \u2014 Pathway Targets & Candidate Approaches Author: Research Team Art of Healing Cancer Credentials: Oncology research & editorial team Updated: August 19, 2025 Estimated reading time: \u224812\u201316 min Primary genes\/pathways with candidate approaches (natural, off-label, approved), a simple prioritization, research-oriented frameworks, and … <a title=\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\" class=\"read-more\" href=\"https:\/\/artofhealingcancer.com\/blogs\/part-8-pathway-targets-candidate-approaches-natural-off-label-approved\/\" aria-label=\"Read more about Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\">Read more<\/a>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14,21],"tags":[],"class_list":["post-472","post","type-post","status-publish","format-standard","hentry","category-breast-cancer","category-stage-4-cancer"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts\/472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/comments?post=472"}],"version-history":[{"count":1,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts\/472\/revisions"}],"predecessor-version":[{"id":473,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts\/472\/revisions\/473"}],"wp:attachment":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/media?parent=472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/categories?post=472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/tags?post=472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

{"id":472,"date":"2025-08-19T01:03:10","date_gmt":"2025-08-18T19:33:10","guid":{"rendered":"https:\/\/artofhealingcancer.com\/blogs\/?p=472"},"modified":"2025-08-19T01:03:10","modified_gmt":"2025-08-18T19:33:10","slug":"part-8-pathway-targets-candidate-approaches-natural-off-label-approved","status":"publish","type":"post","link":"https:\/\/artofhealingcancer.com\/blogs\/part-8-pathway-targets-candidate-approaches-natural-off-label-approved\/","title":{"rendered":"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)"},"content":{"rendered":"\r\n\r\n\r\n \r\n Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)<\/title>\r\n <meta name=\"viewport\" content=\"width=device-width, initial-scale=1\" \/>\r\n <meta name=\"description\" content=\"Primary genes\/pathways in bone-tropic breast cancer with candidate approaches (natural compounds, off-label options, and approved oncology medicines), plus a simple prioritization strategy, practical research-oriented frameworks, and next steps.\" \/>\r\n <meta name=\"robots\" content=\"index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1\" \/>\r\n <meta name=\"author\" content=\"Research Team Art of Healing Cancer\" \/>\r\n <link rel=\"canonical\" href=\"https:\/\/www.example.com\/canonical-placeholder\" \/>\r\n <link rel=\"alternate\" hreflang=\"en\" href=\"https:\/\/www.example.com\/canonical-placeholder\" \/>\r\n\r\n \r\n <meta name=\"keywords\" content=\"bone metastasis, breast cancer, CXCR4 CXCL12, PTK2 FAK, DOCK4, MMPs, PTHrP PTHLH, RANKL OPG, TGF-\u03b2, IL11 IL1B IL6, DKK1 SOST, JAG1 Notch, PI3K AKT mTOR, VEGFA HIF-1\u03b1, HSP90, ESR1 GATA3 NAT1 SCUBE2, antiresorptives, denosumab, zoledronic acid, prioritization strategy, research frameworks\" \/>\r\n\r\n \r\n <meta property=\"og:type\" content=\"article\" \/>\r\n <meta property=\"og:title\" content=\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\" \/>\r\n <meta property=\"og:description\" content=\"Genes\/pathways to know, candidate approaches, a practical prioritization, and research-oriented frameworks for bone-tropic disease.\" \/>\r\n <meta property=\"og:url\" content=\"https:\/\/www.example.com\/canonical-placeholder\" \/>\r\n <meta property=\"og:site_name\" content=\"Art of Healing Cancer\" \/>\r\n <meta property=\"og:locale\" content=\"en_US\" \/>\r\n <meta property=\"og:image\" content=\"https:\/\/www.example.com\/path\/to\/og-image-part8.jpg\" \/>\r\n <meta property=\"og:image:alt\" content=\"Grid of pathways and candidate approaches for bone-tropic metastasis\" \/>\r\n <meta property=\"article:section\" content=\"Oncology\" \/>\r\n <meta property=\"article:published_time\" content=\"2025-08-19T00:00:00+05:30\" \/>\r\n <meta property=\"article:modified_time\" content=\"2025-08-19T00:00:00+05:30\" \/>\r\n\r\n \r\n <meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n <meta name=\"twitter:title\" content=\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\" \/>\r\n <meta name=\"twitter:description\" content=\"Primary genes\/pathways with candidate approaches, prioritization strategy, and practical frameworks.\" \/>\r\n <meta name=\"twitter:image\" content=\"https:\/\/www.example.com\/path\/to\/og-image-part8.jpg\" \/>\r\n <meta name=\"twitter:image:alt\" content=\"Pathway map and treatment layers\" \/>\r\n <meta name=\"twitter:site\" content=\"@ArtOfHealingCancer\" \/>\r\n\r\n \r\n <meta property=\"article:tag\" content=\"Bone Metastasis\" \/>\r\n <meta property=\"article:tag\" content=\"Breast Cancer\" \/>\r\n <meta property=\"article:tag\" content=\"CXCR4\/CXCL12\" \/>\r\n <meta property=\"article:tag\" content=\"RANKL\/OPG\" \/>\r\n <meta property=\"article:tag\" content=\"TGF-\u03b2\" \/>\r\n <meta property=\"article:tag\" content=\"PI3K\u2013AKT\u2013mTOR\" \/>\r\n <meta property=\"article:tag\" content=\"Antiresorptives\" \/>\r\n <meta property=\"article:tag\" content=\"Prioritization Strategy\" \/>\r\n <meta property=\"article:tag\" content=\"Research Frameworks\" \/>\r\n\r\n \r\n <script type=\"application\/ld+json\">\r\n {\r\n \"@context\":\"https:\/\/schema.org\",\r\n \"@type\":\"Article\",\r\n \"headline\":\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\",\r\n \"description\":\"Primary genes\/pathways in bone-tropic breast cancer with candidate approaches (natural compounds, off-label options, and approved oncology medicines), plus a simple prioritization strategy, practical research-oriented frameworks, and next steps.\",\r\n \"inLanguage\":\"en\",\r\n \"datePublished\":\"2025-08-19\",\r\n \"dateModified\":\"2025-08-19\",\r\n \"author\":{\"@type\":\"Organization\",\"name\":\"Research Team Art of Healing Cancer\"},\r\n \"publisher\":{\"@type\":\"Organization\",\"name\":\"Art of Healing Cancer\"},\r\n \"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.example.com\/canonical-placeholder\"},\r\n \"keywords\":[\"Bone Metastasis\",\"Breast Cancer\",\"CXCR4\/CXCL12\",\"RANKL\/OPG\",\"TGF-\u03b2\",\"PI3K\u2013AKT\u2013mTOR\",\"Antiresorptives\",\"Prioritization Strategy\",\"Research Frameworks\",\"MMPs\",\"FAK\",\"Notch\",\"Wnt\",\"VEGFA\/HIF-1\u03b1\",\"HSP90\",\"Dormancy\"],\r\n \"image\":\"https:\/\/www.example.com\/path\/to\/og-image-part8.jpg\",\r\n \"articleSection\":\"Oncology\"\r\n }\r\n <\/script>\r\n\r\n \r\n <script type=\"application\/ld+json\">\r\n {\r\n \"@context\":\"https:\/\/schema.org\",\r\n \"@type\":\"BreadcrumbList\",\r\n \"itemListElement\":[\r\n {\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.example.com\/\"},\r\n {\"@type\":\"ListItem\",\"position\":2,\"name\":\"Art of Healing Cancer\",\"item\":\"https:\/\/www.example.com\/series\/art-of-healing-cancer\"},\r\n {\"@type\":\"ListItem\",\"position\":3,\"name\":\"Part 8 \u2014 Pathway Targets & Candidate Approaches\"}\r\n ]\r\n }\r\n <\/script>\r\n\r\n <style>\r\n \/* ===== Brand tokens (WCAG AA) \u2014 suffix 6112 ===== *\/\r\n :root{\r\n --navy-6112:#0D2B5A; --navy-dark-6112:#0B2240;\r\n --aqua-6112:#00B7C7; --aqua2-6112:#20C2CF;\r\n --white-6112:#FFFFFF; --gray-6112:#E9EEF4;\r\n --graphite-6112:#1F2A37; --muted-6112:#4B5563;\r\n --border-6112:#d7e0ea; --soft-6112:#F7FBFD;\r\n --warn-6112:#B45309; --warnbg-6112:#FFF7ED;\r\n }\r\n html,body{margin:0;padding:0}\r\n body.page-6112{\r\n color:var(--graphite-6112); background:#ffffff;\r\n font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,\"Apple Color Emoji\",\"Segoe UI Emoji\";\r\n font-size:17px; line-height:1.65; -webkit-font-smoothing:antialiased; text-rendering:optimizeLegibility;\r\n }\r\n .wrap-6112{max-width:1080px;margin:0 auto;padding:0 22px}\r\n\r\n \/* ===== Hero ===== *\/\r\n .hero-6112{\r\n background:\r\n radial-gradient(1200px 420px at 18% 0%, rgba(32,194,207,.12), transparent 60%),\r\n linear-gradient(180deg,var(--navy-6112),var(--navy-dark-6112));\r\n color:var(--white-6112);\r\n padding:48px 0 28px;\r\n border-bottom:1px solid rgba(255,255,255,.12);\r\n box-shadow:0 12px 24px rgba(13,43,90,.18);\r\n }\r\n .h1-6112{margin:0 0 10px;font-size:clamp(28px,4.4vw,44px);line-height:1.18;font-weight:850;letter-spacing:.2px}\r\n .underline-6112{height:6px;width:150px;border-radius:999px;background:linear-gradient(90deg,var(--aqua-6112),var(--aqua2-6112));margin-top:10px}\r\n .meta-6112{margin-top:14px;display:flex;flex-wrap:wrap;gap:10px 18px}\r\n .meta-6112 .item-6112{color:#dff7fb;font-weight:700;font-size:14px}\r\n .sub-6112{margin-top:12px;font-size:15px;color:#eef6fb}\r\n\r\n \/* ===== Article card ===== *\/\r\n .card-6112{background:#fff;border:1px solid var(--border-6112);border-radius:18px;box-shadow:0 1px 2px rgba(13,43,90,.06),0 10px 24px rgba(13,43,90,.08);overflow:hidden;margin:28px 0 72px}\r\n .head-6112{padding:16px 20px;background:linear-gradient(180deg,#f4f8fb 0%,#eef5fa 100%);border-bottom:1px solid var(--border-6112)}\r\n .note-6112{border-left:5px solid var(--aqua-6112);background:var(--soft-6112);padding:12px 14px;border-radius:10px;color:var(--muted-6112);font-size:14px}\r\n\r\n \/* ===== Caution box ===== *\/\r\n .caution-6112{display:flex;gap:10px;align-items:flex-start;margin-top:12px;padding:12px 14px;border:1px solid #F5D0A9;background:var(--warnbg-6112);border-radius:12px;color:var(--warn-6112);font-weight:700}\r\n\r\n \/* ===== Bands & pills ===== *\/\r\n .band-6112{\r\n margin:28px 0 12px; padding:0; position:relative;\r\n color:var(--navy-dark-6112); font-size:20px; font-weight:800;\r\n }\r\n .band-6112 span{\r\n display:inline-block; padding:10px 14px; border-radius:12px;\r\n background:linear-gradient(90deg, #f2f7fb, #eaf2f9);\r\n border:1px solid var(--border-6112);\r\n }\r\n .band-6112::before{\r\n content:\"\"; position:absolute; left:-6px; top:50%; transform:translateY(-50%);\r\n width:6px; height:28px; border-radius:4px;\r\n background:linear-gradient(180deg,var(--aqua-6112),var(--aqua2-6112));\r\n }\r\n .pill-6112{display:inline-block;margin:16px 0 8px;padding:6px 12px;background:var(--soft-6112);border:1px solid var(--border-6112);border-radius:999px;font-size:15px;font-weight:800;color:var(--navy-6112)}\r\n .p-6112{margin:0 0 14px}\r\n .ul-6112{margin:0 0 14px 22px}\r\n .ul-6112 li{margin:6px 0}\r\n\r\n \/* ===== TOC ===== *\/\r\n .toc-6112{margin:12px 0 18px;padding:12px 14px;border:1px dashed var(--border-6112);border-radius:12px;background:#FAFDFF}\r\n .toc-6112 a{color:var(--navy-6112);text-decoration:none;font-weight:800}\r\n .toc-6112 a:hover{text-decoration:underline}\r\n\r\n \/* ===== Grid & gene cards ===== *\/\r\n .grid-6112{display:grid;gap:14px;grid-template-columns:1fr}\r\n @media (min-width:760px){.grid-6112{grid-template-columns:1fr 1fr}}\r\n .gene-6112{border:1px solid var(--border-6112);border-radius:14px;background:linear-gradient(180deg,#ffffff 0%,#f8fcfd 100%);box-shadow:0 6px 14px rgba(13,43,90,.06);overflow:hidden}\r\n .geneHead-6112{background:linear-gradient(90deg,var(--aqua-6112),var(--aqua2-6112));color:#fff;padding:10px 14px;display:flex;justify-content:space-between;align-items:center}\r\n .geneTitle-6112{font-weight:900;letter-spacing:.2px}\r\n .geneTag-6112{font-size:12px;font-weight:800;opacity:.95}\r\n .geneBody-6112{padding:12px 14px}\r\n\r\n \/* ===== Summary table ===== *\/\r\n .tableWrap-6112{margin:8px 0 18px; overflow-x:auto}\r\n table.table-6112{width:100%; border-collapse:separate; border-spacing:0; min-width:900px; border:1px solid var(--border-6112); border-radius:12px; overflow:hidden}\r\n .table-6112 caption{text-align:left; padding:10px 12px; font-weight:800; color:var(--navy-dark-6112)}\r\n .table-6112 thead th{background:linear-gradient(90deg,var(--navy-6112),var(--navy-dark-6112));color:#fff;padding:12px 14px;font-size:14px;text-align:left}\r\n .table-6112 tbody td{padding:12px 14px;vertical-align:top;border-top:1px solid var(--border-6112);background:#fff}\r\n .table-6112 tbody tr:nth-child(even) td{background:#f7fbfd}\r\n .kicker-6112{display:inline-block;padding:2px 8px;border-radius:999px;background:var(--aqua-6112);color:#fff;font-size:12px;font-weight:800}\r\n\r\n \/* ===== Details\/summary accordion ===== *\/\r\n details.accord-6112{border-top:1px dashed var(--border-6112);padding-top:10px;margin-top:10px}\r\n details.accord-6112 > summary{cursor:pointer;font-weight:900;color:var(--navy-6112)}\r\n details.accord-6112[open] > summary{opacity:.9}\r\n\r\n \/* ===== Chips ===== *\/\r\n .chips-6112{display:grid;gap:10px;margin-top:12px;grid-template-columns:repeat(auto-fill,minmax(180px,1fr))}\r\n .chip-6112{background:var(--soft-6112);border:1px solid var(--border-6112);padding:10px 12px;border-radius:12px;font-weight:700;color:var(--navy-6112)}\r\n\r\n \/* ===== Footer ===== *\/\r\n .foot-6112{margin-top:22px;font-size:13px;color:var(--muted-6112);border-top:1px dashed var(--border-6112);padding-top:14px}\r\n <\/style>\r\n<\/head>\r\n<body class=\"page-6112\">\r\n <header class=\"hero-6112\" role=\"banner\">\r\n <div class=\"wrap-6112\">\r\n <h1 class=\"h1-6112\">Part 8 \u2014 Pathway Targets & Candidate Approaches<\/h1>\r\n <div class=\"underline-6112\" aria-hidden=\"true\"><\/div>\r\n <div class=\"meta-6112\" aria-label=\"Article metadata\">\r\n <div class=\"item-6112\">Author: <strong>Research Team Art of Healing Cancer<\/strong><\/div>\r\n <div class=\"item-6112\">Credentials: <strong>Oncology research & editorial team<\/strong><\/div>\r\n <div class=\"item-6112\">Updated: <strong>August 19, 2025<\/strong><\/div>\r\n <div class=\"item-6112\">Estimated reading time: <strong>\u224812\u201316 min<\/strong><\/div>\r\n <\/div>\r\n <p class=\"sub-6112\">Primary genes\/pathways with candidate approaches (natural, off-label, approved), a simple prioritization, research-oriented frameworks, and actionable next steps.<\/p>\r\n <\/div>\r\n <\/header>\r\n\r\n <main>\r\n <div class=\"wrap-6112\">\r\n <article class=\"card-6112\" itemscope itemtype=\"https:\/\/schema.org\/Article\">\r\n <div class=\"head-6112\">\r\n <div class=\"note-6112\"><strong>Note:<\/strong> The body text below is your content, structured for readability. Roman numerals are rendered as major section headings. This is educational content and not medical advice.<\/div>\r\n <div class=\"caution-6112\" role=\"note\" aria-label=\"Important notes\">\r\n <div>\u26a0\ufe0f<\/div>\r\n <div>\r\n <strong>Important notes:<\/strong>\r\n <ul class=\"ul-6112\" style=\"margin-top:6px\">\r\n <li>Natural molecules: mostly preclinical evidence; human efficacy\/dosing\/safety for cancer are not established; interactions with therapies are possible.<\/li>\r\n <li>Off-label medicines: require clinician oversight within an evidence-based plan or trials.<\/li>\r\n <li>Approved oncology drugs: listed where they target the biology, even if approvals are for other cancers or endpoints.<\/li>\r\n <li>This section is informational and not medical advice.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n\r\n <div class=\"content-6112\" itemprop=\"articleBody\">\r\n \r\n <nav class=\"toc-6112\" aria-label=\"On-page navigation\">\r\n <strong>Quick nav:<\/strong>\r\n <div class=\"chips-6112\">\r\n <a class=\"chip-6112\" href=\"#primary-genes\">Primary Genes\/Pathways & Candidate Approaches<\/a>\r\n <a class=\"chip-6112\" href=\"#vi-prioritization\">VI) Prioritization Strategy<\/a>\r\n <a class=\"chip-6112\" href=\"#vii-frameworks\">VII) Practical Frameworks<\/a>\r\n <a class=\"chip-6112\" href=\"#viii-spine-recap\">VIII) Spine Recap<\/a>\r\n <a class=\"chip-6112\" href=\"#ix-next-steps\">IX) What To Do Next<\/a>\r\n <\/div>\r\n <\/nav>\r\n\r\n \r\n <h2 id=\"primary-genes\" class=\"band-6112\"><span>Primary Genes\/Pathways With Candidate Approaches (Natural, Off-Label, and Approved Cancer Medications)<\/span><\/h2>\r\n\r\n \r\n <div class=\"tableWrap-6112\" role=\"region\" aria-label=\"Pathway summary table\">\r\n <table class=\"table-6112\">\r\n <caption>Quick reference: pathway \u2192 natural \u2192 off-label \u2192 approved (notes)<\/caption>\r\n <thead>\r\n <tr>\r\n <th scope=\"col\">Pathway \/ Gene<\/th>\r\n <th scope=\"col\">Natural (preclinical)<\/th>\r\n <th scope=\"col\">Off-label (conceptual)<\/th>\r\n <th scope=\"col\">Approved (notes)<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td><span class=\"kicker-6112\">CXCR4 (CXCL12\/SDF-1)<\/span><\/td>\r\n <td>Resveratrol; EGCG<\/td>\r\n <td>Plerixafor (CXCR4 antagonist)<\/td>\r\n <td>No broad solid tumor approval for metastasis prevention; inhibitors investigational; hematologic uses in trials.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">PTK2 \/ FAK<\/span><\/td>\r\n <td>Curcumin<\/td>\r\n <td>Defactinib (investigational)<\/td>\r\n <td>No broad oncology approval; trial-based.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">DOCK4 (Rac motility)<\/span><\/td>\r\n <td>Berberine<\/td>\r\n <td>Fasudil (ROCK inhibitor)<\/td>\r\n <td>No specific approvals for this axis in breast metastasis.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">MMPs (1\/2\/9\/13)<\/span><\/td>\r\n <td>EGCG; Curcumin<\/td>\r\n <td>Doxycycline (MMP modulation)<\/td>\r\n <td>No MMPi approvals for anti-metastatic therapy.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">PTHLH (PTHrP)<\/span><\/td>\r\n <td>Genistein<\/td>\r\n <td>Cinacalcet (contextual)<\/td>\r\n <td>No direct PTHrP drug; downstream control via antiresorptives.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">RANKL \/ OPG axis<\/span><\/td>\r\n <td>Curcumin; Vitamin D \/ Omega-3<\/td>\r\n <td>Oral bisphosphonates (e.g., clodronate)<\/td>\r\n <td>Denosumab; Zoledronic acid; Pamidronate \u2014 reduce SREs in metastatic bone disease.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">TGF-\u03b2 pathway<\/span><\/td>\r\n <td>Sulforaphane; EGCG<\/td>\r\n <td>Losartan (modulating)<\/td>\r\n <td>Multiple agents investigational; no broad approval for prevention.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">IL11 \/ IL1B \/ IL6<\/span><\/td>\r\n <td>Boswellia (AKBA); Curcumin<\/td>\r\n <td>Anakinra; Tocilizumab<\/td>\r\n <td>Approved in inflammatory diseases; oncology use trial-based.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">DKK1 & SOST (Wnt antagonists)<\/span><\/td>\r\n <td>Resveratrol; Quercetin<\/td>\r\n <td>Romosozumab (osteoporosis; CV cautions)<\/td>\r\n <td>Anti-DKK1 agents investigational; no Wnt restoration approval for solid tumors.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">JAG1 \/ Notch<\/span><\/td>\r\n <td>EGCG<\/td>\r\n <td>Gamma-secretase inhibitors (e.g., nirogacestat)<\/td>\r\n <td>Nirogacestat approved for desmoid tumors; breast bone metastasis use investigational.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">PI3K \/ AKT \/ mTOR<\/span><\/td>\r\n <td>Berberine; Resveratrol<\/td>\r\n <td>\u2014<\/td>\r\n <td>Alpelisib; Everolimus; Capivasertib (jurisdiction-dependent).<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">VEGFA \/ HIF-1\u03b1<\/span><\/td>\r\n <td>Curcumin; Resveratrol; Honokiol<\/td>\r\n <td>Bevacizumab (context-dependent)<\/td>\r\n <td>Anti-VEGF\/VEGFR agents approved in various cancers; not for preventing bone metastasis in breast cancer.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">HSP90AA1<\/span><\/td>\r\n <td>Withanolides (Withania somnifera)<\/td>\r\n <td>\u2014<\/td>\r\n <td>No broad approvals for HSP90 inhibitors in solid tumors.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><span class=\"kicker-6112\">ESR1 \/ GATA3 \/ NAT1 \/ SCUBE2<\/span><\/td>\r\n <td>Genistein (context-dependent); Curcumin (immune-niche)<\/td>\r\n <td>Metronomic cyclophosphamide (Treg modulation; exploratory)<\/td>\r\n <td>Endocrine therapy; CDK4\/6 inhibitors; SERD\/SERM combinations (biomarker-guided).<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n\r\n \r\n <div class=\"grid-6112\">\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">CXCR4 (homing\/retention; CXCL12\/SDF-1 axis)<\/div>\r\n <div class=\"geneTag-6112\">Homing<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Resveratrol<\/strong> or <strong>EGCG<\/strong>: Reported to down-modulate CXCR4 signaling and migration in preclinical cancer systems.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Plerixafor<\/strong>: CXCR4 antagonist approved for hematopoietic stem-cell mobilization; conceptually disrupts marrow homing\/retention.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication (any cancer)<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li>None broadly approved for solid tumors to block CXCR4 in metastasis; several CXCR4 inhibitors are investigational in oncology. Some leukemias\/lymphomas use CXCR4-directed strategies in trials.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">PTK2\/FAK (integrin signaling; adhesion\/migration)<\/div>\r\n <div class=\"geneTag-6112\">Adhesion\/Migration<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Curcumin<\/strong>: Inhibits FAK signaling and reduces migration\/invasion in preclinical models.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Defactinib<\/strong>: Oral FAK inhibitor under investigation in solid tumors; not standard of care.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>No FAK inhibitor has a broad oncology approval at present; use is trial-based.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">DOCK4 (Rac-mediated motility)<\/div>\r\n <div class=\"geneTag-6112\">Motility<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Berberine<\/strong>: Broad anti-motility\/invasion effects in preclinical models; may indirectly modulate Rac signaling.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Fasudil<\/strong>: A ROCK inhibitor with cytoskeletal modulation; oncology use is experimental.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>None specific to DOCK\/Rac pathway for breast cancer metastasis; ROCK inhibitors remain investigational in oncology.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">MMPs (MMP1\/2\/9\/13; extracellular matrix remodeling)<\/div>\r\n <div class=\"geneTag-6112\">Invasion<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>EGCG<\/strong> or <strong>curcumin<\/strong>: Preclinical suppression of MMP expression\/activity.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Doxycycline<\/strong>: Sub-antimicrobial dosing can inhibit MMPs; used historically as a broad MMP modulator.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>No MMP inhibitor is approved for anti-metastatic therapy due to past toxicity\/efficacy issues of first-generation agents.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">PTHLH (PTHrP; initiates osteolytic switch)<\/div>\r\n <div class=\"geneTag-6112\">Osteolysis<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Genistein<\/strong>: Preclinical modulation of osteoclastogenesis and the RANKL\/OPG balance.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Cinacalcet<\/strong>: Calcimimetic used for hyperparathyroidism and PTH\/PTHrP-related hypercalcemia; not established as anti-metastatic.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medication<\/summary>\r\n <ul class=\"ul-6112\"><li>No direct PTHrP-targeting drug for cancer; downstream axis control via antiresorptives (see RANKL\/OPG) is standard to prevent skeletal-related events.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">RANKL\/OPG axis (osteoclastogenesis driver)<\/div>\r\n <div class=\"geneTag-6112\">Antiresorptive<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Curcumin<\/strong> or <strong>vitamin D\/omega-3 PUFAs<\/strong>: Preclinical influence on RANKL\/OPG and osteoclastogenesis.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Oral bisphosphonates<\/strong> (e.g., clodronate in certain settings) have been used variably outside strict labels; the class impairs osteoclasts.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Denosumab<\/strong>: Monoclonal antibody to RANKL; approved to prevent skeletal-related events in patients with bone metastases from solid tumors.<\/li>\r\n <li><strong>Zoledronic acid, pamidronate<\/strong>: Intravenous bisphosphonates approved to reduce skeletal-related events in metastatic bone disease.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">TGF-\u03b2 pathway (central amplifier of bone metastasis program)<\/div>\r\n <div class=\"geneTag-6112\">Amplifier<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Sulforaphane<\/strong> or <strong>EGCG<\/strong>: Preclinical attenuation of TGF-\u03b2\/SMAD signaling and TGF-\u03b2-induced EMT.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Losartan<\/strong>: Antifibrotic\/TGF-\u03b2-modulating effects studied in oncology contexts; not standard for metastasis control.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>No TGF-\u03b2 pathway inhibitor has a broad metastasis-prevention approval; multiple agents are investigational in solid tumors.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">IL11, IL1B, IL6 (inflammatory, osteoclastogenic cytokines)<\/div>\r\n <div class=\"geneTag-6112\">Cytokines<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Boswellia serrata (AKBA)<\/strong> or <strong>curcumin<\/strong>: Preclinical suppression of NF-\u03baB\/IL-1\u03b2\/IL-6.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Anakinra<\/strong> (IL-1 receptor antagonist) or <strong>tocilizumab<\/strong> (IL-6R inhibitor): Explored in cancer-related inflammation; investigational in bone-tropic disease.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>IL-6 or IL-1 pathway inhibitors are approved for inflammatory diseases, not for cancer metastasis; in oncology, they\u2019re trial-based for select indications.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">DKK1 and SOST (Wnt antagonists; osteoblast suppression)<\/div>\r\n <div class=\"geneTag-6112\">Wnt<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Resveratrol<\/strong> or <strong>quercetin<\/strong>: Preclinical Wnt modulation that can favor osteoblastogenesis.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Romosozumab<\/strong> (anti-sclerostin) has approvals for osteoporosis, not cancer; application in metastasis is experimental and carries cardiovascular risk considerations.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>Anti-DKK1 agents (e.g., in myeloma) are investigational; no Wnt-restorative drug is approved for solid tumor bone metastasis.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">JAG1\/Notch signaling (microenvironment remodeling)<\/div>\r\n <div class=\"geneTag-6112\">Notch<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>EGCG<\/strong>: Reported preclinical effects on Notch signaling.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Gamma-secretase inhibitors<\/strong> (e.g., nirogacestat): Target Notch activation; toxicity requires careful management; use is trial-based.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Nirogacestat<\/strong> is approved for desmoid tumors (Notch-related biology) in some regions; Notch targeting in breast cancer bone metastasis remains investigational.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">PI3K\/AKT\/mTOR (survival\/growth\/metabolic fitness)<\/div>\r\n <div class=\"geneTag-6112\">Survival<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Berberine<\/strong> or <strong>resveratrol<\/strong>: Preclinical inhibition of PI3K\/AKT\/mTOR; effects on proliferation and EMT.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li>None routinely off-label given existing on-label options in breast cancer.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Alpelisib<\/strong> (PI3K\u03b1 inhibitor) for PIK3CA-mutant HR+ metastatic breast cancer.<\/li>\r\n <li><strong>Everolimus<\/strong> (mTOR inhibitor) for HR+ metastatic breast cancer in combination with endocrine therapy.<\/li>\r\n <li><strong>Capivasertib<\/strong> (AKT inhibitor) has approvals in HR+ breast cancer with pathway alterations in some jurisdictions; availability varies.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">VEGFA\/HIF-1\u03b1 (angiogenesis\/hypoxia response)<\/div>\r\n <div class=\"geneTag-6112\">Angiogenesis<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Curcumin<\/strong>, <strong>resveratrol<\/strong>, or <strong>honokiol<\/strong>: Preclinical anti-angiogenic and HIF-1\u03b1-lowering effects.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Bevacizumab<\/strong> (anti-VEGF): Mixed data in breast cancer; not standard for bone-specific control; consider only in trial settings or specific regulatory contexts.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Bevacizumab<\/strong> and other anti-VEGF\/VEGFR agents (e.g., ramucirumab, aflibercept, sorafenib, sunitinib, pazopanib) are approved in various cancers for anti-angiogenesis, not specifically for bone metastasis prevention in breast cancer.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">HSP90AA1 (chaperone dependency)<\/div>\r\n <div class=\"geneTag-6112\">Stress Support<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Withanolides<\/strong> (Withania somnifera): Preclinical HSP90 modulation.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li>None standard; HSP90 inhibitors remain investigational.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\"><li>No HSP90 inhibitor has broad approval in solid tumors.<\/li><\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n\r\n \r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">ESR1\/GATA3\/NAT1\/SCUBE2 (luminal\/dormancy\/immune niche)<\/div>\r\n <div class=\"geneTag-6112\">Dormancy<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <details class=\"accord-6112\" open>\r\n <summary>Natural molecule<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Genistein<\/strong> (phytoestrogen): Interacts with ER signaling; context-dependent effects; <strong>curcumin<\/strong> for immune-niche modulation preclinically.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Off-label medicine<\/summary>\r\n <ul class=\"ul-6112\"><li><strong>Metronomic cyclophosphamide<\/strong> for Treg modulation is exploratory; use is individualized.<\/li><\/ul>\r\n <\/details>\r\n <details class=\"accord-6112\">\r\n <summary>Approved cancer medications<\/summary>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Endocrine therapies<\/strong> (tamoxifen, aromatase inhibitors, fulvestrant) are standards in HR+ breast cancer.<\/li>\r\n <li><strong>CDK4\/6 inhibitors<\/strong> (palbociclib, ribociclib, abemaciclib) are approved in HR+ metastatic breast cancer and can delay progression, including in bone-dominant disease.<\/li>\r\n <li><strong>SERDs\/SERMs<\/strong> and targeted combinations are approved in specific contexts; selection is biomarker-guided.<\/li>\r\n <\/ul>\r\n <\/details>\r\n <\/div>\r\n <\/section>\r\n <\/div>\r\n\r\n \r\n <h2 id=\"vi-prioritization\" class=\"band-6112\"><span>VI) Prioritization Strategy \u2014 In Simple Terms<\/span><\/h2>\r\n <p class=\"p-6112\">Not every target in the bone metastasis pathway is equally powerful. Some are \u201cmaster switches\u201d that, if flipped off, weaken many downstream processes at once. Others are important but more situational\u2014best addressed if tests show they are dominant in a particular person\u2019s cancer. Prioritization helps decide what to target first.<\/p>\r\n\r\n <div class=\"pill-6112\">Tier 1: Master feedbacks (RANKL\/osteoclasts + TGF-\u03b2)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why top priority:<\/strong> RANKL turns on osteoclasts (the bone-degrading cells). When osteoclasts break down bone, growth factors (especially TGF-\u03b2) pour out of the bone matrix. TGF-\u03b2 then pushes tumor cells to make more osteolysis-promoting signals (like IL-11), \u201cmolecular scissors\u201d (MMPs), and homing\/retention tools (CXCR4), which worsens bone destruction and tumor growth. Together, these two form the core of the vicious cycle.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> Use approved anti-resorptive therapy to reduce bone breakdown (and therefore TGF-\u03b2 release). Consider clinical trials or research strategies aimed at dampening TGF-\u03b2 signaling.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"pill-6112\">Tier 2: Seeding\/retention (CXCR4 axis)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why next:<\/strong> CXCR4 acts like a GPS that guides cancer cells to bone marrow (rich in CXCL12) and helps them stick around.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> Consider clinical trial options that interfere with the CXCR4\u2013CXCL12 connection, especially when molecular testing suggests a bone-tropic profile.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"pill-6112\">Tier 3: Fitness\/expansion (PI3K\/AKT\/mTOR and angiogenesis)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why important:<\/strong> Bone marrow is a tough environment\u2014low oxygen, fluctuating nutrients, immune pressure. PI3K\/AKT\/mTOR helps cancer cells adapt and keep growing. Angiogenesis programs (HIF-1\u03b1\/VEGF) build new blood vessels to feed growth.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> Where approved and biomarker-appropriate, use PI3K\/mTOR\/AKT inhibitors. Consider anti-angiogenic approaches in indicated settings or within trials.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"pill-6112\">Tier 4: Adhesion\/MMP\/Notch\/Wnt (context-driven add-ons)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li><strong>Why conditional:<\/strong> These targets matter, but their dominance varies by tumor.<\/li>\r\n <li><strong>Practical takeaway:<\/strong> When tests show reliance on integrin\/FAK, MMPs, Notch (JAG1), or Wnt antagonism (DKK1\/SOST), consider research-focused strategies alongside Tier 1\u20133 priorities.<\/li>\r\n <\/ul>\r\n\r\n <p class=\"p-6112\"><strong>In short:<\/strong> Start by weakening the core loop (RANKL and TGF-\u03b2), then block homing\/retention (CXCR4), then reduce the tumor\u2019s ability to thrive in bone (PI3K\/mTOR\/AKT and angiogenesis). Add adhesion\/MMP\/Notch\/Wnt tactics based on tumor-specific evidence.<\/p>\r\n\r\n \r\n <h2 id=\"vii-frameworks\" class=\"band-6112\"><span>VII) Practical Frameworks to Explore (Research-Oriented) \u2014 In Simple Terms<\/span><\/h2>\r\n <p class=\"p-6112\">These are examples of how to put the prioritization into action. They are not medical advice but illustrate how clinicians and researchers might tailor strategies to tumor biology.<\/p>\r\n\r\n <div class=\"grid-6112\">\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">ER+ bone-dominant disease with PI3K activation<\/div>\r\n <div class=\"geneTag-6112\">HR+ \/ PI3K<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Build the backbone<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Endocrine therapy (because the tumor is hormone receptor positive).<\/li>\r\n <li>Add a PI3K or mTOR inhibitor if the pathway is activated (based on biomarkers and approvals).<\/li>\r\n <li>Include an anti-resorptive (e.g., denosumab or zoledronic acid) to reduce bone breakdown and TGF-\u03b2 release.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Consider research add-ons<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Clinical trials targeting TGF-\u03b2 (to mute the amplifier) or CXCR4 (to disrupt homing\/retention) when biology suggests these are active.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">Inflammatory signature (high IL-1\u03b2\/IL-6) with osteolytic features<\/div>\r\n <div class=\"geneTag-6112\">Cytokine-high<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Stabilize the bone<\/div>\r\n <ul class=\"ul-6112\"><li>Start anti-resorptive therapy to slow osteoclasts and reduce TGF-\u03b2 release.<\/li><\/ul>\r\n <div class=\"pill-6112\">Treat the whole patient<\/div>\r\n <ul class=\"ul-6112\"><li>Use standard systemic therapy appropriate to subtype (e.g., endocrine therapy for ER+, chemotherapy for other subtypes).<\/li><\/ul>\r\n <div class=\"pill-6112\">Consider research add-ons<\/div>\r\n <ul class=\"ul-6112\"><li>Trials of cytokine blockade (e.g., IL-1 or IL-6 pathway inhibitors) and\/or TGF-\u03b2 modulation.<\/li><\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">High motility\/adhesion signature (FAK\/MMP)<\/div>\r\n <div class=\"geneTag-6112\">Invasion-high<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Target movement and invasion (research-focused)<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Consider trials of FAK inhibitors to impair adhesion\/migration signaling.<\/li>\r\n <li>Dampen local invasion with MMP modulation strategies (e.g., doxycycline) as a research approach.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Combine with core control<\/div>\r\n <ul class=\"ul-6112\"><li>Maintain anti-resorptives and subtype-appropriate systemic therapy to tackle the main loop and disease biology.<\/li><\/ul>\r\n <\/div>\r\n <\/section>\r\n <\/div>\r\n\r\n \r\n <h2 id=\"viii-spine-recap\" class=\"band-6112\"><span>VIII) Why the Spine Often Leads \u2014 But Exceptions Matter (Recap in Simple Terms)<\/span><\/h2>\r\n <ul class=\"ul-6112\">\r\n <li>The spine has a convenient venous \u201chighway\u201d connected to the chest (Batson\u2019s plexus), rich red marrow that attracts tumor cells via CXCL12, and high bone turnover\u2014making it a frequent first site for seeding and growth.<\/li>\r\n <li>But it isn\u2019t always first: pelvis, ribs, and proximal femur are also common early sites. Blood flow, bone stress\/remodeling, tumor surface proteins (chemokine receptors, integrins), and chance can shift the first landing spot.<\/li>\r\n <li><strong>Clinical implication:<\/strong> Do not assume a spinal-first pattern; evaluate the entire skeleton when bone involvement is suspected.<\/li>\r\n <\/ul>\r\n\r\n \r\n <h2 id=\"ix-next-steps\" class=\"band-6112\"><span>IX) What To Do Next: Actionable Steps \u2014 In Simple Terms<\/span><\/h2>\r\n <div class=\"grid-6112\">\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">For patients and caregivers<\/div>\r\n <div class=\"geneTag-6112\">Patient<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Ask about the tumor\u2019s \u201cbone risk\u201d biology<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Features linked to bone spread (ER+\/luminal, high CXCR4, PI3K activation, inflammatory cytokines)? Are biomarker panels available?<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Protect bone health early<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Discuss anti-resorptive therapy; complete dental evaluation first. Ask about calcium\/vitamin D, weight-bearing exercise, and fall-risk reduction.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Speak up about new symptoms<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>New\/worsening back pain, focal bone tenderness, numbness\/weakness \u2192 prompt imaging beyond the spine when warranted.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">For clinicians<\/div>\r\n <div class=\"geneTag-6112\">Clinician<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Stratify risk with what\u2019s available<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Combine clinical factors with molecular markers (luminal signatures, CXCR4, RANKL\/OPG, IL-1\/IL-6, PI3K pathway changes) to tailor surveillance\/supportive care.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Match therapy to biology<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Use guideline-supported systemic therapy for subtype; add anti-resorptives for skeletal event prevention in metastatic bone disease.<\/li>\r\n <li>Explore trial eligibility for TGF-\u03b2, CXCR4, cytokine, FAK, or HSP90-directed strategies where biology points that way.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Choose imaging wisely<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>MRI is excellent for marrow disease; functional PET modalities can detect non-spinal lesions depending on phenotype and availability.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <section class=\"gene-6112\">\r\n <div class=\"geneHead-6112\">\r\n <div class=\"geneTitle-6112\">For researchers<\/div>\r\n <div class=\"geneTag-6112\">Research<\/div>\r\n <\/div>\r\n <div class=\"geneBody-6112\">\r\n <div class=\"pill-6112\">Validate and integrate biomarkers<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Prospective panels\/blood markers for bone tropism: CXCR4\/CXCL12, RANKL\/OPG, IL-11\/IL-1\/IL-6, TGF-\u03b2 responsiveness.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Design enriched trials<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Pair anti-resorptives with targeted inhibitors (TGF-\u03b2, CXCR4, PI3K\/mTOR\/AKT, FAK) in biomarker-selected cohorts; include marrow disease\/SRE\/QoL endpoints.<\/li>\r\n <\/ul>\r\n <div class=\"pill-6112\">Focus on dormancy\/reactivation in ER+ disease<\/div>\r\n <ul class=\"ul-6112\">\r\n <li>Identify triggers that wake dormant cells; test ways to maintain dormancy or eliminate dormant cells without provoking growth.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n <\/div>\r\n\r\n \r\n <h2 class=\"band-6112\"><span>Tags<\/span><\/h2>\r\n <div class=\"chips-6112\" role=\"list\">\r\n <div class=\"chip-6112\" role=\"listitem\">Bone Metastasis<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Breast Cancer<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Antiresorptives<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">RANKL \/ OPG<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">TGF-\u03b2<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">CXCR4 \/ CXCL12<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">PI3K\u2013AKT\u2013mTOR<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">FAK<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">MMPs<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Notch \/ JAG1<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Wnt \/ DKK1 \/ SOST<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Angiogenesis<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Dormancy<\/div>\r\n <div class=\"chip-6112\" role=\"listitem\">Research Frameworks<\/div>\r\n <\/div>\r\n\r\n <div class=\"foot-6112\">\u00a9 2025 Art of Healing Cancer \u00b7 Educational content only; not medical advice.<\/div>\r\n <\/div>\r\n <\/article>\r\n <\/div>\r\n <\/main>\r\n<\/body>\r\n<\/html>\r\n","protected":false},"excerpt":{"rendered":"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved) Part 8 \u2014 Pathway Targets & Candidate Approaches Author: Research Team Art of Healing Cancer Credentials: Oncology research & editorial team Updated: August 19, 2025 Estimated reading time: \u224812\u201316 min Primary genes\/pathways with candidate approaches (natural, off-label, approved), a simple prioritization, research-oriented frameworks, and … <a title=\"Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\" class=\"read-more\" href=\"https:\/\/artofhealingcancer.com\/blogs\/part-8-pathway-targets-candidate-approaches-natural-off-label-approved\/\" aria-label=\"Read more about Part 8: Pathway Targets & Candidate Approaches (Natural, Off-Label & Approved)\">Read more<\/a>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14,21],"tags":[],"class_list":["post-472","post","type-post","status-publish","format-standard","hentry","category-breast-cancer","category-stage-4-cancer"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts\/472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/comments?post=472"}],"version-history":[{"count":1,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts\/472\/revisions"}],"predecessor-version":[{"id":473,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/posts\/472\/revisions\/473"}],"wp:attachment":[{"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/media?parent=472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/categories?post=472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/artofhealingcancer.com\/blogs\/wp-json\/wp\/v2\/tags?post=472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}